The International Society for the Advancement of Spine Surgery released a statement supporting restorative neurostimulation for some patients with mechanical chronic low back pain caused by multifidus dysfunction.
The statement, published in the August 2023 issue of the International Journal of Spine Surgery, recommends restorative neurostimulation for patients who exhausted conventional, conservative treatment options such as physical rehabilitation and steroid injections.
ISASS pointed to studies that consistently show substantial and durable improvements in quality of life, clinical benefits accruing over time, and the majority of patients voluntarily stopped or reduced opioid use after restorative neurostimulation.
"Mechanical chronic low back pain patients are generally not candidates for surgery, have very limited treatment options and utilize significant healthcare resources," Morgan Lorio, MD, ISASS president-elect and board member said in a news release shared with Becker's. "ISASS is proud to respond to the mounting requests for background, supporting literature and evidence and proper coding for the use of restorative neurostimulation in these patients."
Mainstay Medical, which develops Reactiv8, lauded ISASS' statement in a Sept. 6 news release.
"We are pleased that ISASS has published this Statement and recognized the benefits ReActiv8 can provide patients and payers," Jason Hannon, CEO of Mainstay Medical, said. "This builds upon the growing society support for ReActiv8 Restorative Neurostimulation, following the publication last year of the Clinical Guidelines by the American Society of Pain and Neuroscience and the ReActiv8 Position Statement from the Pacific Spine and Pain Society."